Abstract
Immunization and treatment of infectious diseases is been extensively exploited to develop better and safe vaccines. The efforts have been made to improve the effectiveness of vaccines and for this reason nanomedicine emerges as the ultimate alternative. Most common infectious diseases, such as hepatite B virus (HBV), human immunodeficiency virus/ acquired immune deficiency syndrome (HIV/AIDS) malaria, human papillomavirus (HPV) and tuberculosis (TB), have aggressive and prolonged treatments, and for this purpose the development of novel therapeutic systems is a priority aiming at reducing cytotoxicity and drug resistance. Examples of these novel systems are solid lipid nanoparticles (SLN), polymeric, inorganic, metallic, magnetic, viral-based nanoparticles and dendrimers that have been received more attention for their proven efficiency in providing immunization, targeting and triggering antibody response at the cellular level. This review focuses on the efforts that have been made towards the development of novel approaches and also patented and marketed formulations of nanocarrier-based vaccine formulations.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Adachi K, Kawana K, Yokoyama T, Fujii T, Tomio A, Miura S, Tomio K, Kojima S, Oda K, Sewaki T et al (2010) Oral immunization with a Lactobacillus casei vaccine expressing human papillomavirus (HPV) type 16 E7 is an effective strategy to induce mucosal cytotoxic lymphocytes against HPV16 E7. Vaccine 28(16):2810–2817
Ahmad Z, Pandey R, Sharma S, Khuller GK (2008) Novel chemotherapy for tuberculosis: chemotherapeutic potential of econazole- and moxifloxacin-loaded PLG nanoparticles. Int J Antimicrob Agents 31(2):142–146
Aline F, Brand D, Pierre J, Roingeard P, Séverine M, Varrier B, Damier-Poisson I (2009) Dendritic cells loaded with HIV-1 p24 proteins adsorbed on surfactant-free anionic PLA nanoparticles induce enhanced cellular immune responses against HIV-1 after vaccination. Vaccine 27(38):5284–5291
Arias MA, Loxley A, Eatmon C, Van Roey G, Faihrurst D et al (2011) Carnauba wax nanoparticles enhance strong systemic and mucosal cellular and humoral immune responses to HIV-gp140 antigen. Vaccine 29(6):1258–1269
Bajpai SK, Mohan YM, Bajpai M, Tankhiwale R, Thomas V (2007) Synthesis of polymer stabilized silver and gold nanostructures. J Nanosci Nanotechnol 7(9):2994–3010
Bastús NG, Sánchez-Tilló E, Pujals S, Farrera C, Kogan MJ, Giralt E, Celada A, Lloberas J, Puntes V (2009) Peptides conjugated to gold nanoparticles induce macrophage activation. Mol Immunology 46(4):743–748
Bawa R (2005) Will the nanomedicine “patent land grab” thwart commercialization? Nanomedicine 1(4):346–350
Bawa R (2008) Nanoparticle-based therapeutics in humans: a survey. Nanotechonol Law Bus 5(2):135–155
Bawa R (2010) Nanopharmaceuticals. Eur J Nanomedicine 3(1):34–40
Bharali DJ, Pradhan V, Elkin G, Qi W, Hutson A, Mousa SA, Thanavala Y (2008) Novel nanoparticles for the delivery of recombinant hepatitis B vaccine. Nanomedicine 4(4):311–317
Bivas-Benita M, Lin MY, Bal SM, van Meijgaarden KE, Franken KLMC, Friggen AH et al (2009) Pulmonary delivery of DNA encoding Mycobacterium tuberculosis latency antigen Rv1733c associated to PLGA-PEI nanoparticles enhances T cell responses in a DNA prime/protein boost vaccination regimen in mice. Vaccine 27(30):4010–4017
Boas U, Heegaard PM (2004) Dendrimers in drug research. Chem Soc Rev 33(1):43–63
Bolhassani A, Safaiyan S, Sima R (2011) Improvement of different vaccine delivery systems for cancer therapy. Mol Cancer 10(3). doi:10.1186/1476-4598-10-3
Borges O, Silva M, de Souza A, Borchard G, Junginger HE, Cordeiro-da-Silva A (2008) Alginate coated chitosan nanoparticles are an effective subcutaneous adjuvant for hepatitis B surface antigen. Int Immunopharmacol 8(13–14):1773–1780
Bourne N, Stanberry LR, Kern ER, Holan G, Matthews B, Bernstein DI (2000) Dendrimers, a new class of candidate topical microbicides with activity against herpes simplex virus infection. Antimicrob Agents Chemother 44(9):2471–2474
Carcaboso AM, Hernandez RM, Igartua M, Gascon AR, Rosas JE, Patarroyo ME, Pedraz JL (2003) Immune response after oral administration of the encapsulated malaria synthetic peptide SPf66. Int J Pharm 260(2):273–282
Castro-Longoria E, Vilchis-Nestor AR, Avalos-Borja M (2011) Biosynthesis of silver, gold and bimetallic nanoparticles using the filamentous fungus Neurospora crassa. Colloids Surf B Biointerfaces 83(1):42–48
Cech PG, Aebi T, Abbdallah MS, Mpina M, Machunda EB, Westerfeld N et al (2011) Virosome-formulated Plasmodium falciparum AMA-1 & CSP derived peptides as malaria vaccine: randomized phase 1b trial in semi-immune adults & children. PLoS One 6(7):e22273
Chen YS, Hung YC, Lin WH, Huang GS (2010) Assessment of gold nanoparticles as a size-dependent vaccine carrier for enhancing the antibody response against synthetic foot-and-mouth disease virus peptide. Nanotechnology 21(19):195101
Combadiere B, Mahe B (2008) Particle-based vaccines for transcutaneous vaccination. Comp Immunol Microbiol Infect Dis 31(2–3):293–315
FDA Consumer Health Information (2011) FDA Opens Dialogue on ‘Nano’ Regulation. http://www.fda.gov/downloads/ForConsumers/ConsumerUpdates/UCM258691.pdf. Accessed 16 Jun 2011
Daftarian P, Kaifer AE, Li W, Blomberg BB, Frasca D, Roth F, Chowdhury R, Berg EA, et al (2011) Peptide-conjugated PAMAM dendrimer as a universal DNA vaccine platform to target antigen-presenting cells. Cancer Res. 71(24):7452–7462
das Neves J, Amiji MM, Bahia MF, Sarmento B (2010) Nanotechnology-based systems for the treatment and prevention of HIV/AIDS. Adv Drug Deliv Rev 62(4–5):458–477
Dutta T, Garg M, Jain NK (2008a) Targeting of efavirenz loaded tuftsin conjugated poly(propyleneimine) dendrimers to HIV infected macrophages in vitro. Eur J Pharm Sci 34(2–3):181–189
Dutta T, Garg M, Jain NK (2008b) Poly(propyleneimine) dendrimer and dendrosome mediated genetic immunization against hepatitis B. Vaccine 26(27–28):3389–3394
Dutta T, Burgess M, McMillan NA, Parekh HS (2010) Dendrosome-based delivery of siRNA against E6 and E7 oncogenes in cervical cancer. Nanomedicine 6(3):463–470
Fangueiro JF, Gonzalez-Mira E, Martins-Lopes P, Egea MA, Garcia ML, Souto SB, Souto EB (2011) A novel lipid nanocarrier for insulin delivery: production, characterization and toxicity testing. Pharm Dev Technol. doi:10.3109/10837450.2011.591804
Faraji AH, Wipf P (2009) Nanoparticles in cellular drug delivery. Bioorg Med Chem 17(8):2950–2962
Glenn GM, Alving CR (2011) Method of transcutaneous immunization using antigen. United States Patent 20110243979
Gordon S, Teichmann E, Young K, Finnie K, Rades T, Hook S (2010) In vitro and in vivo investigation of thermosensitive chitosan hydrogels containing silica nanoparticles for vaccine delivery. Eur J Pharm Sci 41(2):360–368
Govan VA, Rybicki EP, Williamson AL (2008) Therapeutic immunisation of rabbits with cottontail rabbit papillomavirus (CRPV) virus-like particles (VLP) induces regression of established papillomas. Virol J 5:45
Guo Z, Pereira T, Choi O, Wang Y, Thomas Hahn H (2006) Surface functionalized alumina nanoparticle filled polymeric nanocomposites with enhanced mechanical properties. J Mater Chem 16:2800–2808
Gupta U, Jain NK (2010) Non-polymeric nano-carriers in HIV/AIDS drug delivery and targeting. Adv Drug Deliv Rev 62(4–5):478–490
Gupta PN, Mahor S, Rawat A, Khatri K, Goyal A, Vyas SP (2006) Lectin anchored stabilized biodegradable nanoparticles for oral immunization: 1. Development and in vitro evaluation. Int J Pharm 318(1–2):163–173
Hatz C, Beck B, Steffen R, Genton B, d’Acremont V, Loutan L, HartmannK HC (2011) Real-life versus package insert: a post-marketing study on adverse-event rates of the virosomal hepatitis A vaccine Epaxal® in healthy travellers. Vaccine 29(31):5000–5006
Heike B (2011) Structural properties of solid lipid based colloidal drug delivery systems. Curr Opin Colloid Interface Sci 16(5):405–411
Heimo B, Hubert P, Zielinski C, Jensen-Jarolim E, Scheiner O (2010) Oral vaccination United States Patent 20100183684
Hock SC, Ying YM, Lai WC (2011) A review of the current scientific and regulatory status of nanomedicines and the challenges ahead. PDA J Pharm Sci Technol 65(2):177–195
Holgate ST (2010) Exposure, uptake, distribution and toxicity of nanomaterials in humans. J Biomed Nanotechnol 6(1):1–19
Hu K, Dou J, Yu F, He X, Yuan X, Wang Y, Liu C, Gu N (2010) An ocular mucosal administration of nanoparticles containing DNA vaccine pRSC-gD-IL-21 confers protection against mucosal challenge with herpes simplex virus type 1 in mice. Vaccine 29(7):1455–1462
Hunter R, Strickland F, Kezdy F (1981) The adjuvant activity of nonionic block polymer surfactantsI. The role of hydrophile-lipophile balance. J Immunol 127(3):1244–1250
Jain V, Vyas SP, Kohli DV (2009a) Well-defined and potent liposomal hepatitis B vaccines adjuvanted with lipophilic MDP derivatives. Nanomedicine 5(3):334–344
Jain AK, Goyal AK, Gupta PN, Khatri K, Mishra N, Mehta A, Mangal S, Vyas SP (2009b) Synthesis, characterization and evaluation of novel triblock copolymer based nanoparticles for vaccine delivery against hepatitis B. J Control Rel 136(2):161–169
Joshi MD, Muller RH (2009) Lipid nanoparticles for parenteral delivery of actives. Eur J Pharm Biopharm 71(2):161–172
Ju-Nam Y, Lead JR (2008) Manufactured nanoparticles: an overview of their chemistry, interactions and potential environmental implications. Sci Total Environ 400(1–3):396–414
Kisich KO, Gelperina S, Higgins MP, Wilson S, Shipulo E, Oganesyan E, Heifets L (2007) Encapsulation of moxifloxacin within poly(butyl cyanoacrylate) nanoparticles enhances efficacy against intracellular Mycobacterium tuberculosis. Int J Pharm 345(1–2):154–162
Koppad S, Raj GD, Rej GD, Gopinath VP, Kirubaharan JJ, Thangavelu A, Thiagarajan V (2011) Calcium phosphate coupled Newcastle disease vaccine elicits humoral and cell mediated immune responses in chickens. Res Vet Sci 91(3):384–390
Kumari A, Yadav SK, Yadav SC (2010) Biodegradable polymeric nanoparticles based drug delivery systems. Colloids Surf B Biointerfaces 75(1):1–18
Lamalle-Bernard D, Munier S, Compagnon C, Charles MH, Kalyanaraman VS, Delair T, Varrier B, Ataman-Önal Y (2006) Coadsorption of HIV-1 p24 and gp120 proteins to surfactant-free anionic PLA nanoparticles preserves antigenicity and immunogenicity. J Control Rel 115(1):57–67
Lara HH, Ayala-Nuñez NV, Ixtepan-Turrent L, Rodriguez-Padilla C (2010) Mode of antiviral action of silver nanoparticles against HIV-1. J Nanobiotechnol 8(1). doi:10.1186/1477-3155-8-1
Letchford K, Burt H (2007) A review of the formation and classification of amphiphilic block copolymer nanoparticulate structures: micelles, nanospheres, nanocapsules and polymersomes. Eur J Pharm Biopharm 65(3):259–269
Look M, Bandyopadhyay A, Blum GS, Fahmy TM (2010) Application of nanotechnologies for improved immune response against infectious diseases in the developing world. Adv Drug Deliv Rev 62(4–5):378–393
Luo D, Han E, Belcheva N, Saltzman WM (2004) A self-assembled, modular DNA delivery system mediated by silica nanoparticles. J Control Rel 95(2):333–341
Ma W, Smith T, Bogin V, Zhang Y, Ozkan C, Ozkan M et al (2011) Enhanced presentation of MHC class Ia, Ib and class II-restricted peptides encapsulated in biodegradable nanoparticles: a promising strategy for tumor immunotherapy. J Transl Med 9:34
Martins S, Sarmento B, Ferreira DC, Souto EB (2007) Lipid-based colloidal carriers for peptide and protein delivery–liposomes versus lipid nanoparticles. Int J Nanomedicine 2(4):595–607
Mata E, Carcaboso AM, Hernandez RM, Igartua M, Corradin G, Pedraz JL (2007) Adjuvant activity of polymer microparticles and Montanide ISA 720 on immune responses to Plasmodium falciparum MSP2 long synthetic peptides in mice. Vaccine 25(5):877–885
Matsuo K, Koizumi H, Akashi M, Nakagawa S, Fujita T, Yamamoto A, Okada N (2011) Intranasal immunization with poly(gamma-glutamic acid) nanoparticles entrapping antigenic proteins can induce potent tumor immunity. J Control Rel 152(2):310–316
Minev BR (2008) Use of polymeric nanoparticles for vaccine delivery. United States Patent 20080044484
Moghimi SM, Moghimi M (2008) Enhanced lymph node retention of subcutaneously injected IgG1-PEG2000-liposomes through pentameric IgM antibody-mediated vesicular aggregation. Biochim Biophys Acta 1778(1):51–55
Mora-Huertas CE, Fessi H, Elaissari A (2010) Polymer-based nanocapsules for drug delivery. Int J Pharm 385:113–142
Moretton MA, Glisoni RJ, Chiappetta DA, Sosnik A (2010) Molecular implications in the nanoencapsulation of the anti-tuberculosis drug rifampicin within flower-like polymeric micelles. Colloids Surf B Biointerfaces 79(2):467–479
Muchow M, Maincent P, Muller RH (2008) Lipid nanoparticles with a solid matrix (SLN, NLC, LDC) for oral drug delivery. Drug Dev Ind Pharm 34(12):1394–1405
Muller RH, Mader K (2000) Solid lipid nanoparticles (SLN) for controlled drug delivery - a review of the state of the art. Eur J Pharm Biopharm 50:161–177
Nagy JO, Bargatze RF, Jutila JW, Cutler JE, Glee PM (2007) Nanoparticle vaccines. United States Patent 7285289
Nayak AP, Tiyaboonchai W, Patankar S, Madhusudhan B, Souto EB (2010) Curcuminoids-loaded lipid nanoparticles: novel approach towards malaria treatment. Colloids Surf B Biointerfaces 81(1):263–273
Nishioka Y, Yoshino H (2001) Lymphatic targeting with nanoparticulate system. Adv Drug Deliv Rev 47(1):55–64
Noguez C, Garzon IL (2009) Optically active metal nanoparticles. Chem Soc Rev 38(3):757–771
Oberdorster G (2010) Safety assessment for nanotechnology and nanomedicine: concepts of nanotoxicology. J Intern Med 267(1):89–105
Panda AK, Vibhu K (2010) Polymer particles based vaccine. United States Patent 20100112078
Pittet LAM, Gao Y, Zepp C, Lipford GB (2011) Synthetic virus-like particles conjugated to human papillomavirus capsid peptides for use as vaccines United States Patent 20110171248
Plummer EM, Manchester M (2011) Viral nanoparticles and virus-like particles: platforms for contemporary vaccine design. Wiley Interdiscip Rev Nanomed Nanobiotechnol 3(2):174–193
Rao JP, Geckeler KE (2011) Polymer nanoparticles: preparation techniques and size-control parameters. Prog Polym Sci 36(7):887–913
Reddy ST, Berk DA, Jain RK, Swartz MA (2006a) A sensitive in vivo model for quantifying interstitial convective transport of injected macromolecules and nanoparticles. J Appl Physiol 101(4):1162–1169
Reddy ST, Swartz MA, Hubbell JA (2006b) Targeting dendritic cells with biomaterials: developing the next generation of vaccines. Trends Immunol 27(12):573–579
Santos-Magalhaes NS, Mosqueira VC (2010) Nanotechnology applied to the treatment of malaria. Adv Drug Deliv Rev 62(4–5):560–575
Schmid G (2008) Ionically cross-linked gold clusters and gold nanoparticles. Angew Chem Int Ed Engl 47(19):3496–3498
Sheng KC, Kalkanidis M, Pouniotis DS, Esparon S, Tang CK, Apostolopoulos V, Pietersz GA (2008) Delivery of antigen using a novel mannosylated dendrimer potentiates immunogenicity in vitro and in vivo. Eur J Immunol 38(2):424–436
Shriver LP, Koudelka KJ, Manchester M (2009) Viral nanoparticles associate with regions of inflammation and blood brain barrier disruption during CNS infection. J Neuroimmunol 211(1–2):66–72
Singh KK, Vingkar SK (2008) Formulation, antimalarial activity and biodistribution of oral lipid nanoemulsion of primaquine. Int J Pharm 347(1–2):136–143
Skwarczynski M, Toth I (2011) Peptide-based subunit nanovaccines. Curr Drug Deliv 8(3):282–289
Slowing II, Vivero-Escoto JL, Wu CW, Lin VSY (2008) Mesoporous silica nanoparticles as controlled release drug delivery and gene transfection carriers. Adv Drug Deliv Rev 60(11):1278–1288
Sosnik A, Carcaboso AM, Glisoni RJ, Moretton MA, Chiappetta DA (2010) New old challenges in tuberculosis: potentially effective nanotechnologies in drug delivery. Adv Drug Deliv Rev 62(4–5):547–559
Souto EB (2009) A special issue on Lipid-based delivery systems (liposomes, lipid nanoparticles, lipid matrices and medicines). J Biomed Nanotechnol 5(4):315–316
Souto EB, Doktorovova S (2009) Solid lipid nanoparticle formulations pharmacokinetic and biopharmaceutical aspects in drug delivery. Methods Enzymol 464:105–129
Steinmetz NF (2010) Viral nanoparticles as platforms for next-generation therapeutics and imaging devices. Nanomed Nanotechnol Biol Med 6(5):634–641
Ulery BD, Kumar D, Ramer-Tait A, Metzger DW, Wannemuehler MJ, Narasimhan B (2011) Design of a protective single-dose intranasal nanoparticle-based vaccine platform for respiratory infectious diseases. PLoS One 6(3):e17642
Wang J, Feng SS, Wang S, Chen ZY (2010) Evaluation of cationic nanoparticles of biodegradable copolymers as siRNA delivery system for hepatitis B treatment. Int J Pharm 400(1–2):194–200
Wei HJ, Chang W, Lin SC, Liu WC, Chang DK, Chong P, Wu SC (2011) Fabrication of influenza virus-like particles using M2 fusion proteins for imaging single viruses and designing vaccines. Vaccine 29(41):7163–7172
Wiechers J, Souto EB (2010) Solid Lipid Nanoparticles (SLNs) and Nanostructured Lipid Carriers (NLCs) as Novel Delivery Systems for Cosmetic Actives. Part I. Cosmetics and Toiletries 10:22–30
Wilson-Welder JH, Torres MP, Kipper MJ, Mallapragada SK, Wannemuehler MJ, Narasimhan B (2009) Vaccine adjuvants: current challenge and future approaches. J Pharm Sci 98:1278–1316
Wu L, Zhang J, Watanabe W (2011) Physical and chemical stability of drug nanoparticles. Adv Drug Deliv Rev 63(6):456–469
Xiang SD, Selomulya C, Ho J, Apostolopoulos V, Plebanski M (2010) Delivery of DNA vaccines: an overview on the use of biodegradable polymeric and magnetic nanoparticles. Wiley Interdiscip Rev Nanomed Nanobiotechnol 2(3):205–218
Xu FJ, Zeng QH, Lu GQ, Yu AB (2006) Inorganic nanoparticles as carriers for efficient cellular delivery. Chem Eng Science 61:1027–1040
Zolnik BS, Gonzalez-Fernandez A, Sadrieh N, Dobrovolskaia MA (2010) Nanoparticles and the immune system. Endocrinology 151(2):458–465
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2012 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Fangueiro, J.F., Severino, P., Souto, S.B., Souto, E.B. (2012). Nanomedicines for Immunization and Vaccines. In: Souto, E. (eds) Patenting Nanomedicines. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-29265-1_15
Download citation
DOI: https://doi.org/10.1007/978-3-642-29265-1_15
Published:
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-29264-4
Online ISBN: 978-3-642-29265-1
eBook Packages: Humanities, Social Sciences and LawLaw and Criminology (R0)